Business and Finance

Acquisition of healthcare logistics company to play a role in delivery of pharma and biologic treatments

Division will operate under SCHOTT Pharma AG & Co. KGaA

How cross-functional commercialization teams can hone their role within clinical management pathways, communicate value to all stakeholders, achieve excellence in evidence generation, and maximize the opportunities of digital technologies

Price tag for bivalent dose was $1.74 billion

New 154,000 square-foot center will house several of the pharma company’s business units

New property is valued at $323 million

Focus on operational excellence is playing a major role in this effort, company says

CDMO’s Ireland campus will increase in capacity by 50% as a result

Expanded partnership revolves around hemophilia A therapeutics

Transaction totals about $3 billion

Project is expected to grow CRDO’s capacity by over 150,000 square feet

Facility, with expected completion of 2025, will specialize in mRNA-based therapies

Maria Whitman, global head of ZS’s pharmaceutical and biotech practice, talks about the upheaval of the pharma business model and what it means for sales reps; the current skills gap in the marketplace; and how mega-mergers could soon be back on the agenda

Deal expands CDMO’s presence in Europe

Investment will grow manufacturing capabilities at Winchester site

East Syracuse site will serve as a hub for company’s US biologics CDMO business

Deal establishes company’s presence in Mexico

Will be investing up to $100 million to expand presence in Taiwan

Location will feature aseptic fill-finish technology

Deal for PROPENSITY4 grows company’s data analytics knowledge

Per supply chain agreement, CDMO will provide analytical product support

Among efforts, part of center’s focus revolves providing tools for product commercialization

Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines

Cambridge, MA facility to be home to Alexion corporate HQ

Deal for New Jersey cell therapy site totals $44.5 million

Deal adds biopharma services to its capabilities

Will address biologics drug substance and drug product manufacturing services

Factory will reportedly provide capability of manufacturing 3-4 vaccines simultaneously

Acquisition works toward addressing needs of regenerative medicine industry

Includes a 36,000-square-foot addition to Charlottetown location